Net Sales +1%; Organic
Sales +3%
Diluted EPS and Core EPS
$1.52, each +11%
MAINTAINS FISCAL YEAR
SALES AND CASH RETURN GUIDANCE
RAISES EPS GROWTH
GUIDANCE
The Procter & Gamble Company (NYSE:PG) reported third
quarter fiscal year 2024 net sales of $20.2 billion, an increase of
one percent versus the prior year. Organic sales, which excludes
the impacts of foreign exchange and acquisitions and divestitures,
increased three percent. Diluted net earnings per share were $1.52,
an increase of 11% versus prior year.
Operating cash flow was $4.1 billion, and net earnings were $3.8
billion for the quarter. Adjusted free cash flow productivity was
87%, which is calculated as operating cash flow excluding capital
spending, as a percentage of net earnings. The Company returned
$3.3 billion of cash to shareowners via approximately $2.3 billion
of dividend payments and $1 billion of share repurchases. The
dividend increase declared earlier this month marks the 68th
consecutive year that P&G has increased its dividend and the
134th consecutive year that P&G has paid a dividend since its
incorporation in 1890.
Third Quarter ($ billions,
except EPS)
GAAP
2024
2023
% Change
Non-GAAP*
2024
2023
% Change
Net Sales
20.2
20.1
1%
Organic Sales
n/a
n/a
3%
Diluted EPS
1.52
1.37
11%
Core EPS
1.52
1.37
11%
*Please refer to Exhibit 1 - Non-GAAP
Measures for the definition and reconciliation of these measures to
the related GAAP measures.
“We delivered solid sales and strong earnings growth in the
third quarter despite multiple headwinds, enabling us to raise our
EPS growth guidance and maintain our top-line outlook for the
fiscal year,” said Jon Moeller, Chairman of the Board, President
and Chief Executive Officer. “We remain committed to our integrated
strategy of a focused product portfolio of daily use categories
where performance drives brand choice, superiority — across product
performance, packaging, brand communication, retail execution and
consumer and customer value — productivity, constructive disruption
and an agile and accountable organization. We are increasing
investments in superiority to drive market growth and sustain
strong momentum. We have confidence this remains the right strategy
to deliver balanced growth and value creation.”
January - March Quarter Discussion
Net sales in the third quarter of fiscal year 2024 were $20.2
billion, a one percent increase versus the prior year. Organic
sales, which exclude the impacts of foreign exchange and
acquisitions and divestitures, increased three percent. The organic
sales increase was driven by a three percent increase from higher
pricing. Mix and volume had a neutral impact on sales for the
quarter.
January - March
2024
Volume
Foreign
Exchange
Price
Mix
Other (2)
Net
Sales
Organic
Volume
Organic
Sales
Net Sales
Drivers (1)
Beauty
1%
(3)%
4%
(1)%
1%
2%
1%
3%
Grooming
2%
(7)%
10%
(1)%
(1)%
3%
2%
10%
Health Care
(4)%
(1)%
4%
3%
—%
2%
(4)%
2%
Fabric & Home Care
1%
(1)%
2%
—%
—%
2%
1%
3%
Baby, Feminine & Family Care
(3)%
(2)%
2%
1%
—%
(2)%
(3)%
—%
Total P&G
—%
(2)%
3%
—%
—%
1%
—%
3%
(1)
Net sales percentage changes are
approximations based on quantitative formulas that are consistently
applied.
(2)
Other includes the sales mix
impact from acquisitions and divestitures and rounding impacts
necessary to reconcile volume to net sales.
- Beauty segment organic sales increased three percent versus
year ago. Skin and Personal Care organic sales declined low single
digits due to lower sales of the super-premium SK-II brand,
partially offset by volume growth from innovation in Personal Care.
Hair Care organic sales increased high single digits driven by
increased pricing in Latin America, Europe and North America.
- Grooming segment organic sales increased ten percent versus
year ago driven primarily by higher pricing in Latin America and
Europe. Volume growth was partially offset by unfavorable product
mix.
- Health Care segment organic sales increased two percent versus
year ago. Oral Care organic sales increased mid-single digits due
to premium product mix, partially offset by volume declines mainly
in Asia Pacific and North America. Personal Health Care organic
sales increased low single digits driven by increased pricing,
partially offset by volume declines due to lower incidence of cough
and cold.
- Fabric and Home Care segment organic sales increased three
percent versus year ago. Fabric Care organic sales increased low
single digits due to increased pricing and favorable geographic mix
due to growth in North America and Europe. Home Care organic sales
increased high single digits due to increased pricing and volume
growth from innovation.
- Baby, Feminine and Family Care segment organic sales were
unchanged versus year ago. Baby Care organic sales decreased
mid-single digits due primarily to pricing-related volume declines,
partially offset by favorable product mix and devaluation-related
price increases. Feminine Care organic sales increased low single
digits driven by increased pricing and favorable product mix,
partially offset by pricing-related volume declines. Family Care
organic sales increased low single digits due to volume growth,
partially offset by unfavorable product mix.
Diluted net earnings per share increased by 11% to $1.52, driven
by an increase in net sales and an increase in core operating
margin. Currency-neutral EPS were up 18% versus the prior year
EPS.
Reported gross margin for the quarter increased 300 basis points
versus the prior year. Core gross margin for quarter increased 310
basis points and 400 basis points on a currency-neutral basis. The
increase was driven by benefits of 260 basis points from gross
productivity savings, 130 basis points of favorable commodity costs
and 130 basis points from increased pricing. These were partially
offset by 100 basis points of unfavorable gross margin product mix
and 20 basis points of product reinvestments and other impacts.
Selling, general and administrative expense (SG&A) as a
percentage of sales increased 210 basis points versus year ago and
170 basis points on a currency-neutral basis. The increase was
driven by 330 basis points of reinvestments, partially offset by 60
basis points of productivity savings and 100 basis points of net
sales growth leverage and other impacts.
Operating margin for the quarter increased 90 basis points
versus the prior year, 220 basis points on a currency-neutral
basis. Operating margin included gross productivity savings of 320
basis points.
Fiscal Year 2024 Guidance
P&G maintained its guidance range for fiscal 2024 all-in
sales growth to be in the range of two to four percent versus the
prior year. Foreign exchange is expected to be a headwind of
approximately one to two percentage points to all-in sales growth.
The Company also maintained its outlook for organic sales growth in
the range of four to five percent.
P&G raised its fiscal 2024 diluted net earnings per share
growth from a range of -1% to inline to a range of one to two
percent versus fiscal 2023 EPS of $5.90. P&G also raised its
fiscal 2024 core net earnings per share growth from a range of
eight to nine percent to a range of 10% to 11% versus fiscal 2023
EPS.
P&G now expects unfavorable foreign exchange rates will be a
headwind of approximately $600 million after tax. The Company
expects the net impact of interest expense and interest income to
be a headwind of approximately $100 million after tax. The Company
now expects a benefit of approximately $900 million after tax from
favorable commodity costs for fiscal year 2024.
The Company is unable to reconcile its forward-looking non-GAAP
cash flow and tax rate measures without unreasonable efforts given
the unpredictability of the timing and amounts of discrete items,
such as acquisitions, divestitures, or impairments, which could
significantly impact GAAP results.
P&G now expects a core effective tax rate of 20% to 21% in
fiscal 2024.
Capital spending is estimated to be approximately 4% of fiscal
2024 net sales.
P&G continues to expect adjusted free cash flow productivity
of 90% and expects to pay more than $9 billion in dividends and to
repurchase $5 to $6 billion of common shares in fiscal 2024.
Forward-Looking Statements
Certain statements in this release, other than purely historical
information, including estimates, projections, statements relating
to our business plans, objectives and expected operating results,
and the assumptions upon which those statements are based, are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements generally are
identified by the words "believe," "project," "expect,"
"anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result" and similar expressions.
Forward-looking statements are based on current expectations and
assumptions, which are subject to risks and uncertainties that may
cause results to differ materially from those expressed or implied
in the forward-looking statements. We undertake no obligation to
update or revise publicly any forward-looking statements, whether
because of new information, future events or otherwise, except to
the extent required by law.
Risks and uncertainties to which our forward-looking statements
are subject include, without limitation: (1) the ability to
successfully manage global financial risks, including foreign
currency fluctuations, currency exchange or pricing controls and
localized volatility; (2) the ability to successfully manage local,
regional or global economic volatility, including reduced market
growth rates, and to generate sufficient income and cash flow to
allow the Company to effect the expected share repurchases and
dividend payments; (3) the ability to manage disruptions in credit
markets or to our banking partners or changes to our credit rating;
(4) the ability to maintain key manufacturing and supply
arrangements (including execution of supply chain optimizations and
sole supplier and sole manufacturing plant arrangements) and to
manage disruption of business due to various factors, including
ones outside of our control, such as natural disasters, acts of war
(including the Russia-Ukraine War) or terrorism or disease
outbreaks; (5) the ability to successfully manage cost fluctuations
and pressures, including prices of commodities and raw materials
and costs of labor, transportation, energy, pension and healthcare;
(6) the ability to stay on the leading edge of innovation, obtain
necessary intellectual property protections and successfully
respond to changing consumer habits, evolving digital marketing and
selling platform requirements and technological advances attained
by, and patents granted to, competitors; (7) the ability to compete
with our local and global competitors in new and existing sales
channels, including by successfully responding to competitive
factors such as prices, promotional incentives and trade terms for
products; (8) the ability to manage and maintain key customer
relationships; (9) the ability to protect our reputation and brand
equity by successfully managing real or perceived issues, including
concerns about safety, quality, ingredients, efficacy, packaging
content, supply chain practices or similar matters that may arise;
(10) the ability to successfully manage the financial, legal,
reputational and operational risk associated with third-party
relationships, such as our suppliers, contract manufacturers,
distributors, contractors and external business partners; (11) the
ability to rely on and maintain key company and third-party
information and operational technology systems, networks and
services and maintain the security and functionality of such
systems, networks and services and the data contained therein; (12)
the ability to successfully manage uncertainties related to
changing political and geopolitical conditions and potential
implications such as exchange rate fluctuations and market
contraction; (13) the ability to successfully manage current and
expanding regulatory and legal requirements and matters (including,
without limitation, those laws and regulations involving product
liability, product and packaging composition, intellectual
property, labor and employment, antitrust, privacy and data
protection, tax, the environment, due diligence, risk oversight,
accounting and financial reporting) and to resolve new and pending
matters within current estimates; (14) the ability to manage
changes in applicable tax laws and regulations; (15) the ability to
successfully manage our ongoing acquisition, divestiture and joint
venture activities, in each case to achieve the Company's overall
business strategy and financial objectives, without impacting the
delivery of base business objectives; (16) the ability to
successfully achieve productivity improvements and cost savings and
manage ongoing organizational changes while successfully
identifying, developing and retaining key employees, including in
key growth markets where the availability of skilled or experienced
employees may be limited; (17) the ability to successfully manage
the demand, supply and operational challenges, as well as
governmental responses or mandates, associated with a disease
outbreak, including epidemics, pandemics or similar widespread
public health concerns; (18) the ability to manage the
uncertainties, sanctions and economic effects from the war between
Russia and Ukraine; and (19) the ability to successfully achieve
our ambition of reducing our greenhouse gas emissions and
delivering progress towards our environmental sustainability
priorities. For additional information concerning factors that
could cause actual results and events to differ materially from
those projected herein, please refer to our most recent 10-K, 10-Q
and 8-K reports.
About Procter & Gamble
P&G serves consumers around the world with one of the
strongest portfolios of trusted, quality, leadership brands,
including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®,
Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head &
Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®,
Tide®, Vicks®, and Whisper®. The P&G community includes
operations in approximately 70 countries worldwide. Please visit
https://www.pg.com for the latest news and information about
P&G and its brands. For other P&G news, visit us at
https://www.pg.com/news.
THE PROCTER & GAMBLE
COMPANY AND SUBSIDIARIES
Consolidated Earnings
Information
Three Months Ended March
31
Amounts in millions except per share
amounts
2024
2023
% Chg
NET SALES
$
20,195
$
20,068
1
%
Cost of products sold
9,855
10,404
(5
)%
GROSS PROFIT
10,340
9,664
7
%
Selling, general and administrative
expense
5,880
5,416
9
%
Indefinite-lived intangible asset
impairment charge
—
—
OPERATING INCOME
4,460
4,248
5
%
Interest expense
(233
)
(222
)
5
%
Interest income
104
83
25
%
Other non-operating income, net
260
179
45
%
EARNINGS BEFORE INCOME TAXES
4,592
4,288
7
%
Income taxes
812
864
(6
)%
NET EARNINGS
3,781
3,424
10
%
Less: Net earnings attributable to
noncontrolling interests
27
27
—
%
NET EARNINGS ATTRIBUTABLE TO PROCTER
& GAMBLE
$
3,754
$
3,397
11
%
EFFECTIVE TAX RATE
17.7
%
20.1
%
NET EARNINGS PER COMMON SHARE
(1)
Basic
$
1.56
$
1.41
11
%
Diluted
$
1.52
$
1.37
11
%
DIVIDENDS PER COMMON SHARE
$
0.9407
$
0.9133
DILUTED WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
2,472.0
2,473.2
COMPARISONS AS A % OF NET SALES
Basis Pt Chg
Gross profit
51.2
%
48.2
%
300
Selling, general and administrative
expense
29.1
%
27.0
%
210
Operating income
22.1
%
21.2
%
90
Earnings before income taxes
22.7
%
21.4
%
130
Net earnings
18.7
%
17.1
%
160
Net earnings attributable to Procter &
Gamble
18.6
%
16.9
%
170
(1)
Basic net earnings per common
share and Diluted net earnings per common share are calculated on
Net earnings attributable to Procter & Gamble
Certain columns and rows may not add due to
rounding.
THE PROCTER & GAMBLE
COMPANY AND SUBSIDIARIES
Consolidated Earnings
Information
Three Months Ended March 31,
2024
Amounts in millions
Net Sales
% Change
Versus Year
Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year
Ago
Net Earnings/(Loss)
% Change
Versus Year
Ago
Beauty
$
3,550
2
%
$
753
(1
)%
$
587
(3
)%
Grooming
1,539
3
%
379
(1
)%
303
(2
)%
Health Care
2,873
2
%
687
3
%
525
—
%
Fabric & Home Care
7,169
2
%
1,692
10
%
1,301
11
%
Baby, Feminine & Family Care
4,936
(2
)%
1,299
8
%
997
8
%
Corporate
128
N/A
(218
)
N/A
68
N/A
Total Company
$
20,195
1
%
$
4,592
7
%
$
3,781
10
%
Three Months Ended March 31,
2024
Net Sales
Drivers (1)
Volume
Organic
Volume
Foreign
Exchange
Price
Mix
Other (2)
Net Sales
Beauty
1
%
1
%
(3
)%
4
%
(1
)%
1
%
2
%
Grooming
2
%
2
%
(7
)%
10
%
(1
)%
(1
)%
3
%
Health Care
(4
)%
(4
)%
(1
)%
4
%
3
%
—
%
2
%
Fabric & Home Care
1
%
1
%
(1
)%
2
%
—
%
—
%
2
%
Baby, Feminine & Family Care
(3
)%
(3
)%
(2
)%
2
%
1
%
—
%
(2
)%
Total Company
—
%
—
%
(2
)%
3
%
—
%
—
%
1
%
(1)
Net sales percentage changes are
approximations based on quantitative formulas that are consistently
applied.
(2)
Other includes the sales mix
impact from acquisitions and divestitures and rounding impacts
necessary to reconcile volume to net sales.
Certain columns and rows may not add due
to rounding.
THE PROCTER & GAMBLE
COMPANY AND SUBSIDIARIES
Consolidated Statements of
Cash Flows
Nine Months Ended March
31
Amounts in
millions
2024
2023
CASH, CASH EQUIVALENTS AND RESTRICTED
CASH, BEGINNING OF PERIOD
$
8,246
$
7,214
OPERATING ACTIVITIES
Net earnings
11,830
11,346
Depreciation and amortization
2,135
2,008
Share-based compensation expense
433
406
Deferred income taxes
(206
)
(360
)
Gain on sale of assets
(51
)
(4
)
Indefinite-lived intangible asset
impairment charge
1,341
—
Changes in:
Accounts receivable
(692
)
(301
)
Inventories
(47
)
(503
)
Accounts payable and accrued and other
liabilities
56
(609
)
Other operating assets and liabilities
(1,196
)
(839
)
Other
490
363
TOTAL OPERATING ACTIVITIES
14,092
11,507
INVESTING ACTIVITIES
Capital expenditures
(2,539
)
(2,328
)
Proceeds from asset sales
77
9
Acquisitions, net of cash acquired
(21
)
(714
)
Other investing activity
(503
)
331
TOTAL INVESTING ACTIVITIES
(2,986
)
(2,702
)
FINANCING ACTIVITIES
Dividends to shareholders
(6,863
)
(6,710
)
Additions to short-term debt with original
maturities of more than three months
2,961
13,778
Reductions in short-term debt with
original maturities of more than three months
(7,523
)
(9,134
)
Net additions/(reductions) to other
short-term debt
2,331
(387
)
Additions to long-term debt
1,598
2,569
Reductions in long-term debt
(2,335
)
(1,877
)
Treasury stock purchases
(3,490
)
(7,353
)
Impact of stock options and other
965
861
TOTAL FINANCING ACTIVITIES
(12,356
)
(8,253
)
EFFECT OF EXCHANGE RATE CHANGES ON
CASH, CASH EQUIVALENTS AND RESTRICTED CASH
(168
)
(170
)
CHANGE IN CASH, CASH EQUIVALENTS AND
RESTRICTED CASH
(1,418
)
382
CASH, CASH EQUIVALENTS AND RESTRICTED
CASH, END OF PERIOD
$
6,828
$
7,596
Certain columns and rows may not add due
to rounding.
THE PROCTER & GAMBLE
COMPANY AND SUBSIDIARIES
Condensed Consolidated Balance
Sheets
Amounts in
millions
March 31, 2024
June 30, 2023
Cash and cash equivalents
$
6,828
$
8,246
Accounts receivable
6,124
5,471
Inventories
7,077
7,073
Prepaid expenses and other current
assets
2,428
1,858
TOTAL CURRENT ASSETS
22,458
22,648
Property, plant and equipment, net
22,027
21,909
Goodwill
40,567
40,659
Trademarks and other intangible assets,
net
22,193
23,783
Other noncurrent assets
12,353
11,830
TOTAL ASSETS
$
119,598
$
120,829
Accounts payable
$
13,691
$
14,598
Accrued and other liabilities
10,921
10,929
Debt due within one year
7,729
10,229
TOTAL CURRENT LIABILITIES
32,340
35,756
Long-term debt
24,253
24,378
Deferred income taxes
6,284
6,478
Other noncurrent liabilities
6,386
7,152
TOTAL LIABILITIES
69,264
73,764
TOTAL SHAREHOLDERS' EQUITY
50,333
47,065
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY
$
119,598
$
120,829
Certain columns and rows may not add due
to rounding.
The Procter & Gamble Company
Exhibit 1: Non-GAAP Measures
The following provides definitions of the non-GAAP measures used
in Procter & Gamble's April 19, 2024 earnings release and the
reconciliation to the most closely related GAAP measures. We
believe that these measures provide useful perspective on
underlying business trends (i.e., trends excluding non-recurring or
unusual items) and results and provide a supplemental measure of
period-to-period results. The non-GAAP measures described below are
used by management in making operating decisions, allocating
financial resources and for business strategy purposes. These
measures may be useful to investors, as they provide supplemental
information about business performance and provide investors a view
of our business results through the eyes of management. Certain of
these measures are also used to evaluate senior management and are
a factor in determining their at-risk compensation. These non-GAAP
measures are not intended to be considered by the user in place of
the related GAAP measures but rather as supplemental information to
our business results. These non-GAAP measures may not be the same
as similar measures used by other companies due to possible
differences in method and in the items or events being adjusted.
The Company is not able to reconcile its forward-looking non-GAAP
cash flow and tax rate measures because the Company cannot predict
the timing and amounts of discrete items such as acquisition and
divestitures, which could significantly impact GAAP results.
The Core earnings measures included in the following
reconciliation tables refer to the equivalent GAAP measures
adjusted as applicable for the following items:
- Incremental restructuring: The
Company has historically had an ongoing level of restructuring
activities of approximately $250 - $500 million before tax. On
December 5, 2023, the Company announced a limited market portfolio
restructuring of its business operations, primarily in certain
Enterprise Markets, including Argentina and Nigeria. The adjustment
to Core earnings includes the restructuring charges that exceed the
normal, recurring level of restructuring charges.
- Intangible asset impairment: The
Company recognized in the three months ended December 31, 2023, a
non-cash, after-tax impairment charge of $1.0 billion ($1.3 billion
before tax) to adjust the carrying value of the Gillette intangible
asset acquired as part of the Company's 2005 acquisition of The
Gillette Company.
We do not view the above items to be part of our sustainable
results, and their exclusion from core earnings measures provides a
more comparable measure of year-on-year results. These items are
also excluded when evaluating senior management in determining
their at-risk compensation.
Organic sales growth: Organic sales
growth is a non-GAAP measure of sales growth excluding the impacts
of acquisitions and divestitures and foreign exchange from
year-over-year comparisons. We believe this measure provides
investors with a supplemental understanding of underlying sales
trends by providing sales growth on a consistent basis. This
measure is used in assessing the achievement of management goals
for at-risk compensation.
Core EPS and Currency-neutral EPS:
Core earnings per share, or Core EPS, is a measure of diluted net
earnings per common share (diluted EPS) adjusted for items as
indicated. Currency-neutral EPS is a measure of the Company's Core
EPS excluding the incremental current year impact of foreign
exchange. Management views these non-GAAP measures as useful
supplemental measures of Company performance over time.
Core gross margin and Currency-neutral
Core gross margin: Core gross margin is a measure of the
Company's gross margin adjusted for items as indicated.
Currency-neutral Core gross margin is a measure of the Company's
Core gross margin excluding the incremental current year impact of
foreign exchange. Management believes these non-GAAP measures
provide a supplemental perspective to the Company’s operating
efficiency over time.
Core selling, general and administrative
(SG&A) expense as a percentage of sales and Currency-neutral
Core SG&A expense as a percentage of sales: Core
SG&A expense as a percentage of sales is a measure of the
Company's selling, general and administrative expense as a
percentage of net sales adjusted for items as indicated.
Currency-neutral Core SG&A expense as a percentage of sales is
a measure of the Company's Core selling, general and administrative
expense as a percentage of net sales excluding the incremental
current year impact of foreign exchange. Management believes these
non-GAAP measures provide a supplemental perspective to the
Company's operating efficiency over time.
Core operating margin and Currency-neutral
Core operating margin: Core operating margin is a measure of
the Company's operating margin adjusted for items as indicated.
Currency-neutral Core operating margin is a measure of the
Company's Core operating margin excluding the incremental current
year impact of foreign exchange. Management believes these non-GAAP
measures provide a supplemental perspective to the Company’s
operating efficiency over time.
Adjusted free cash flow: Adjusted
free cash flow is defined as operating cash flow less capital
expenditures. Adjusted free cash flow represents the cash that the
Company is able to generate after taking into account planned
maintenance and asset expansion. We view adjusted free cash flow as
an important measure because it is one factor used in determining
the amount of cash available for dividends, share repurchases,
acquisitions and other discretionary investments.
Adjusted free cash flow
productivity: Adjusted free cash flow productivity is
defined as the ratio of adjusted free cash flow to net earnings
excluding the Gillette intangible asset impairment charge. We view
adjusted free cash flow productivity as a useful measure to help
investors understand P&G’s ability to generate cash. Adjusted
free cash flow productivity is used by management in making
operating decisions, in allocating financial resources and for
budget planning purposes. This measure is also used in assessing
the achievement of management goals for at-risk compensation.
THE PROCTER & GAMBLE COMPANY
AND SUBSIDIARIES
Reconciliation of Non-GAAP
Measures
Three Months Ended March 31,
2024
Three Months Ended
March 31, 2023
Amounts in
millions except per share amounts
As Reported
(GAAP)
Incremental
Restructuring
Intangible
Impairment
Core
(Non-GAAP)
As Reported
(GAAP) (1)
Cost of products sold
$
9,855
$
(13
)
$
—
$
9,842
$
10,404
Gross profit
10,340
13
—
10,353
9,664
Gross margin
51.2
%
0.1
%
—
%
51.3
%
48.2
%
Currency impact to Core gross margin
0.9
%
Currency-neutral Core gross margin
52.2
%
Selling, general and administrative
expense
5,880
3
—
5,883
5,416
Selling, general and administrative
expense as a % of net sales
29.1
%
—
%
—
%
29.1
%
27.0
%
Currency impact to Core selling, general
and administrative expense as a % of net sales
(0.4
)%
Currency-neutral Core selling, general and
administrative expense as a % of net sales
28.7
%
Operating income
4,460
10
—
4,471
4,248
Operating margin
22.1
%
—
%
—
%
22.1
%
21.2
%
Currency impact to Core operating
margin
1.3
%
Currency-neutral Core operating margin
23.4
%
Income taxes
812
—
—
812
864
Net earnings attributable to P&G
3,754
10
—
3,763
3,397
Core EPS
Diluted net earnings per common share
(2)
$
1.52
$
—
$
—
$
1.52
$
1.37
Currency impact to Core EPS
$
0.09
Currency-neutral Core EPS
$
1.61
Diluted weighted average common shares
outstanding
2,472.0
2,473.2
Common shares outstanding - March 31,
2024
2,360.1
(1) For the period ending March 31, 2023, there were no
adjustments to or reconciling items for Core EPS.
(2) Diluted net earnings per common share are calculated on Net
earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Gross margin
300
BPS
Core gross margin
310
BPS
Currency-neutral Core gross margin
400
BPS
Selling, general and administrative
expense as a % of net sales
210
BPS
Core selling, general and administrative
expense as a % of net sales
210
BPS
Currency-neutral Core selling, general and
administrative as a % of net sales
170
BPS
Operating margin
90
BPS
Core operating margin
90
BPS
Currency-neutral Core operating margin
220
BPS
Diluted EPS
11
%
Core EPS
11
%
Currency-neutral Core EPS
18
%
Organic sales growth:
January - March
2024
Net
Sales Growth
Foreign
Exchange
Impact
Acquisition &
Divestiture
Impact/Other (1)
Organic
Sales
Growth
Beauty
2%
3%
(2)%
3%
Grooming
3%
7%
—%
10%
Health Care
2%
1%
(1)%
2%
Fabric & Home Care
2%
1%
—%
3%
Baby, Feminine & Family Care
(2)%
2%
—%
—%
Total Company
1%
2%
—%
3%
(1)
Acquisition & Divestiture
Impact/Other includes the volume and mix impact of acquisitions and
divestitures and rounding impacts necessary to reconcile net sales
to organic sales.
Total
Company
Net
Sales Growth
Combined
Foreign Exchange &
Acquisition/Divestiture Impact/Other (1)
Organic
Sales Growth
FY 2024 (Estimate)
+2% to +4%
+1% to +2%
+4% to +5%
(1)
Combined Foreign Exchange &
Acquisition/Divestiture Impact/Other includes foreign exchange
impacts, the volume and mix impact of acquisitions and divestitures
and rounding impacts necessary to reconcile net sales to organic
sales.
Core EPS growth:
Total
Company
Diluted
EPS Growth
Impact
of Incremental Non-Core Items (1)
Core EPS
Growth
FY 2024 (Estimate)
+1% to +2%
+9%
+10% to +11%
(1)
Includes the Gillette intangible
asset impairment charge and incremental non-core restructuring
charges announced in December 2023.
Adjusted free cash flow (dollar amounts in
millions):
Three Months Ended March 31,
2024
Operating Cash Flow
Capital
Spending
Adjusted
Free Cash Flow
$4,088
$(797)
$3,291
Adjusted free cash flow productivity
(dollar amounts in millions):
Three Months Ended March 31,
2024
Adjusted
Free Cash Flow
Net
Earnings
Adjustments to
Net
Earnings (1)
Net
Earnings
as
Adjusted
Adjusted
Free Cash Flow
Productivity
$3,291
$3,781
$—
$3,781
87%
(1)
For the period ending March 31,
2024, there were no adjustments to Net Earnings.
Certain columns and rows may not add due
to rounding.
Category: PG-IR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240419054233/en/
P&G Media: Wendy
Kennedy, 513.780.7212 Jennifer Corso, 513.983.2570
P&G Investor Relations:
John Chevalier, 513.983.9974
Procter and Gamble (NYSE:PG)
Historical Stock Chart
From Mar 2025 to Apr 2025
Procter and Gamble (NYSE:PG)
Historical Stock Chart
From Apr 2024 to Apr 2025